Results for “ ”

Entry Author Date Location
Bio Roundup: Trump Backlash, Verdine Plans, Sarepta Sale & More 02/24/17 National
Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO 02/23/17 Boston
Seventh Sense Gets Initial FDA Clearance for Simple Blood-Draw Device 02/23/17 Boston
Aiming At P53, Cancer’s Hard Target, PMV Pharma Raises $74M 02/22/17 New York
Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking Shares 02/21/17 San Diego
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More 02/17/17 National
Rhythm Raises $41M to Bankroll Late-Stage Push For Obesity Drug 02/16/17 Boston
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
Patent Judges’ CRISPR Ruling For Broad Leaves Daylight For Berkeley 02/15/17 Boston
Merck Alzheimer Drug Is Latest To Fail In A Big Study 02/15/17 National
Hologic Expands Into Medical Aesthetics With $1.4B Cynosure Deal 02/14/17 Boston
FDA Turmoil, Biology Mystery On List Of Hurdles For Microbiome Drugs 02/14/17 New York
Senate Confirms Price for HHS, But Stock Deals Still Raise Questions 02/10/17 National
Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs 02/10/17 Boston
Bio Roundup: Travel Ban Block, Gilead Shock, Dean Kamen Talk & More 02/10/17 National
Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation 02/10/17 National
Xconomy Is Growing: We Need Great Salespeople in SF, Texas, and NY 02/09/17 National
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data 02/09/17 New York
Biotech Leaders Sign Letter Condemning Trump’s Travel Ban 02/07/17 National
Kentucky Biotech CEO’s Message For McConnell: I’ll Be Muslim, Too 02/07/17 National
With $294M, Kamen Hopes to Bring Regenerative Medicine “Up to Scale” 02/06/17 Boston
Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins 02/03/17 National
Tarveda Nabs $30M More as Versant Helps Fund Cancer Drug Push 02/02/17 Boston
Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof 02/02/17 Boston
Seed-Stage Deals Show Growing Diversity of Agtech Investments 02/01/17 Raleigh Durham
Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths 02/01/17 Boston
Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy 01/31/17 Boston
Still No Official Word From Biopharma Groups About Trump Travel Ban 01/31/17 National
Seres Dissects Failed Microbiome Drug Trial, Suggests Changes to FDA 01/31/17 Boston
Page 1 of 119 next page »